EGFR and interstitial lung disease: There are no reports of a significant difference in the incidence of ILD between EGFR-TKIs (gefitinib 1.3–2.2%, erlotinib 0.6–1.5%, afatinib 0.2–0.6%, and osimertinib 3.0%) [14,16,23].